NCT06154187View on ClinicalTrials.gov

Study to Evaluate the Efficacy and Safety of PBK_L2201 in Postmenopausal Women With Osteoporosis

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 29, 2024

Primary Completion Date

May 31, 2025

Study Completion Date

November 30, 2025

Conditions
Osteoporosis
Interventions
DRUG

PBK_L2201

Abaloparatide-SC 80 μg was to be self-administered daily using a Pen Injector device.

DRUG

Placebo

Placebo was formulated similar to abaloparatide-SC.

Trial Locations (1)

Unknown

The Catholic University of Korea Yeouido Saint Mary's Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Pharmbio Korea Co., Ltd.

INDUSTRY